Analysis of the phase I/IIa randomized, placebo-controlled APPROACH trial showed that all of the tested varieties still had a "robust humoral and cellular responses even after 1 year," according to Frank Tomaka, MD, of developer Janssen, the Johnson & Johnson subsidiary.
Trending:
Next-gen HIV vaccines safe with durable immune response